Jay Hancock

Jay Hancock was a senior correspondent for KFF Health News until he retired in Feburary 2022.

jayhancock@protonmail.com
@jayhancock1

Chronically Ill, Traumatically Billed: The $123,000 Medicine For MS

Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.

The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide

Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.